nach oben

Journal of Neurology

Erschienen in:

01.01.2014 | Review

Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported

verfasst von: Axel Petzold, Gordon T. Plant

Erschienen in: Journal of Neurology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Chronic relapsing inflammatory optic neuropathy (CRION) is an entity that was described in 2003. Early recognition of patients suffering from CRION is relevant because of the associated risk for blindness if treated inappropriately. It seems timely to have a clinical review on this recently defined entity. A systematic literature review, irrespective of language, retrieved 22 case series and single reports describing 122 patients with CRION between 2003 and 2013. We review the epidemiology, diagnostic workup, differential diagnosis, and treatment (acute, intermediate, and long term) in view of the collective data. These data suggest that CRION is a distinct nosological entity, which is seronegative for anti-aquaporin four auto-antibodies and recognized by and managed through its dependency on immuno-suppression. Revised diagnostic criteria are proposed in light of the data compromising a critical discussion of relevant limitations.

At later stages optic nerve atrophy may become more prominent and is structurally related to RNFL and GCL loss on retinal OCT.

Kidd D, Burton B, Plant GT, Graham EM (2003) Chronic relapsing inflammatory optic neuropathy (CRION). Brain 126:276–284CrossRefPubMed

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker B G (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–12CrossRefPubMed

Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70(23):2197–20CrossRefPubMed

Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune-mediated optic neuritis. J Neurol Neurosurg Psychiatry 81(1):109–111CrossRefPubMed

Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, Franciotta D, Ruprecht K, Kuenz B, Rommer P, Kristoferitsch W, Wildemann B, Vincent A (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1-2):158–162CrossRefPubMed

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Munch C, Winkelmann A, Zettl UK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9(1):14PubMedCentralCrossRefPubMed

Kinoshita M, Nakatsuji Y, Moriya M, Okuno T, Kumanogoh A, Nakano M, Takahashi T, Fujihara K, Tanaka K, Sakoda S (2009) Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20(5):508–512CrossRefPubMed

Sabater L, Giralt A, Boronat A, Hankiewicz K, Blanco Y, Llufriu S, Alberch J, Graus F, Saiz A (2009) Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: An in vitro study. J Neuroimmunol 215(1–2):31–35

Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RH et al (2002) Markers for different glial cell responses in multiple sclerosis: Clinical and pathological correlations. Brain 125:1462–1473CrossRefPubMed

10.

Malmestroem C, Haghighi S, Rosengren L, Andersen O, Lycke J (2003) Neurofilament light protein and glial fibrillary acidic protein as biological markers in ms. Neurology 61(12):1720–1725CrossRef

11.

Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y (2009) Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 80(5):575–577CrossRefPubMed

12.

Petzold A, Marignier R, Verbeek MM, Confavreux C (2011) Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? preliminary results on 188 patients with different neurological diseases. J Neurol Neurosurg Psychiatry 82(4):467–469CrossRefPubMed

13.

Storoni M, Petzold A, Plant GT (2011) The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS One, 6(8):e23489PubMedCentralCrossRefPubMed

14.

Storoni M, Verbeek MM, Illes Z, Marignier R, Teunissen CE, Grabowska M, Confavreux C, Plant GT, Petzold A (2012) Serum GFAP levels in optic neuropathies. J Neurol Sci 317(1–2):117–122CrossRefPubMed

15.

De Benito L, Muñoz L, Martínez M, Cortés C, De Andrés C (2005) Recurrent bilateral inflammatory idiopathic optic neuropathy treated with mycophenolate mofetil: clinical and radiological course. Neuroophthalmology 29:149–159CrossRef

16.

Herrero Latorre R, Fernandez Perez S, De La Mata G, Idoipe M, Satue M, Garcia Martin E (2011) A case of chronic relapsing inflammatory optic neuropathy (CRION). Acta Ophthalmologica 89:s248CrossRef

17.

Kurz D, Egan RA, Rosenbaum JT (2005) Treatment of corticosteroid dependent optic neuropathy with intravenous immunoglobulin. Am J Ophthalmol 140(6):1132–1133CrossRefPubMed

18.

Kaut O, Klockgether T (2008) 51-year-old female with steroid-responsive optic neuropathy: a new case of chronic relapsing inflammatory optic neuropathy (CRION). J Neurol 255(9):1419–1420CrossRefPubMed

19.

Plant GT, Sibtain NA, Thomas D (2011) Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series. Mult Scler Int 2011:815068PubMedCentralPubMed

20.

Pérez-Díaz H, Casado JL, Uclés-Sánchez A, Saiz A (2007) Chronic relapsing inflammatory optic neuropathy (CRION) without detection of IgG-NMO antibodies. Neurologia 22(8):553–555PubMed

21.

Prendiville C, O’Doherty M, Moriarty P, Cassidy L (2008) The use of infliximab in ocular inflammation. Br J Ophthalmol 92(6):823–825CrossRefPubMed

22.

Ramos Fernández C, García Oliva I, Reyes Rodríguez MA, Francisco Hernández F, Tandón Cárdenes L, González Hernández A (2011) Neuropatíaóptica inflamatoria recurrente crónica (CRION): a propósito de un caso. Archivos de la Sociedad Canaria de Oftalmología 22:93–98

23.

Saini M, Khurana D (2010) Chronic relapsing inflammatory optic neuropathy. Ann Indian Acad Neurol 13(1):61–63PubMedCentralCrossRefPubMed

24.

Samra A, Ramtahal J (2012) Recurrent subacute visual loss presenting in a 52-year-old Caucasian woman with chronic relapsing inflammatory optic neuropathy: a case report. J Med Case Rep 6(1):15PubMedCentralCrossRefPubMed

25.

Kubrak M, Czajor K, Turno-Krecicka A (2012) A 45-year-old woman with sudden loss of vision a case report. Neuro-ophthalmology, 36(S1):30, Abstracts of the 2012 Meeting of the International Neuro-Ophthalmology Society, Singapore

26.

Stiebel-Kalish H, Hammel N, van Everdingen J, Huna-Baron R, Lee AG (2010) Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy. Can J Ophthalmol 45(1):71–75CrossRefPubMed

27.

Thorne JE, Wittenberg S, Kedhar SR, Dunn JP, Jabs DA (2007) Optic neuropathy complicating multifocal choroiditis and panuveitis. Am J Ophthalmol 143(4):721–723PubMedCentralCrossRefPubMed

28.

Pandit L, Shetty R, Misri Z, Bhat S, Amin H, Pai V, Rao R (2012) Optic neuritis: experience from a south Indian demyelinating disease registry. Neurol India 60(5):470–475CrossRefPubMed

29.

Kurne A, Krabudak R, Cakmakli GY et al (2010) Recurrent optic neuritis: clues from a long-term follow-up study of recurrent and bilateral optic neuritis patients. Eye Brain 2:15–20

30.

Wiryasaputra S, Lim SA (2010) Relationship between visual acuity, visual field and retinal nerve fibre layer thickness in optic neuritis. In: INOS, p 46. Tan Tock Seng Hospital, Singapore

31.

Benoilid A, Tilikete C, Arndt C, Collengues N, Vignal-Clermont C, Vighetto A, De Seze J (2012) Relapsing inflammatory optic neuropathy: a multicenter study of 62 patients. Neurology, 78:p 07.251, Abstract, American Academy of Neurology

32.

Palmi-Cortes I, Meca-Lallana V, Canneti B, Valenzuela-Rojas FJ, Vivancos J (2012) Recurrent optic neuritis: the importance of the differential diagnosis. Mult Scler p 215, Abstract ECTRIMS

33.

Falcao B, Bichuetti DB, Oliveira EML, Nmo GAA (2012) CRION or MS: what we say when we have recurrent optic neuritis. Mult Scler p 604, Abstract. ECTRIMS

34.

Wong S, Cleary G, Graham EM, Plant GT (2012) Blindness cured: response to late steroids in. J Neurol Neurosurg Psychiatry 83:A28, Abstract. ABN

35.

Myers TD, Smith JR, Wertheim MS, Egan RA, Shults WT, Rosenbaum JT (2004) Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid-dependent optic neuritis not associated with demyelinating disease. Br J Ophthalmol 88(5):673–680PubMedCentralCrossRefPubMed

36.

Storoni M, Pittock SJ, Weinshenker BG, Plant GT (2012) Optic neuritis in an ethnically diverse population: higher risk of atypical cases in patients of African or African-Caribbean heritage. J Neurol Sci 312(1–2):21–25PubMedCentralCrossRefPubMed

37.

Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. the optic neuritis study group. N Engl J Med 326(9):581–588CrossRef

38.

Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 115(6):1079–1082CrossRef

39.

Lepore FE (1991) The origin of pain in optic neuritis. Determinants of pain in 101 eyes with optic neuritis. Arch Neurol 48(7):748–749CrossRefPubMed

40.

Thouvenot E, Mura F, De Verdal M, Carlander B, Charif M, Schneider C, Navarre S, Camu W (2012) Ipsilateral uveitis and optic neuritis in multiple sclerosis. Mult Scler Int 2012:372361PubMedCentralPubMed

41.

Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665–671PubMedCentralCrossRefPubMed

42.

Petzold A, Plant GT (2012) The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies. Mult Scler Int 2012:217802PubMedCentralPubMed

43.

Stangel M, Fredrikson S, Meinl E, Petzold A, Stve O, Tumani H (2013) The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 9(5):267–276

44.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302PubMedCentralCrossRefPubMed

45.

Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, Petzold A (2012) The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment. PLoS One 7(4):e34823PubMedCentralCrossRefPubMed

46.

Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ (2012) Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 135(6):1786–1793

47.

Balk LJ, Killestein J, Polman CH, Uitdehaag BMJ, Petzold A (2012) Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain 135(Pt 12):e226CrossRefPubMed

48.

Petzold A (2012) Microcystic macular oedema in ms: T2 lesion or black hole. Lancet Neurol 11(11):933–934CrossRefPubMed

49.

Hickman SJ, Dalton CM, Miller DH, Plant GT (2002) Management of acute optic neuritis. Lancet 360:1953–1962CrossRefPubMed

50.

Graves J, Balcer LJ (2010) Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol 4:1409–1422PubMedCentralPubMed

51.

Zettl UK, Stve O, Patejdl R (2010) Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 11(3):167–173CrossRef

52.

Seguro LPC, Rosario C, Shoenfeld Y (2013) Long-term complications of past glucocorticoid use. Autoimmun Rev 12(5):629–632CrossRefPubMed

53.

van Gijn J (2007) Cerebral vasoconstriction, headache and sometimes stroke: one syndrome or many? Brain 130(Pt 12):3060–3062CrossRefPubMed

54.

Morrow MJ, Wingerchuk D (2012) Neuromyelitis optica. J Neuroophthalmol 32(2):154–166CrossRefPubMed

Titel: Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported
verfasst von: Axel Petzold
Gordon T. Plant
Publikationsdatum: 01.01.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 1/2014
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-6957-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

The high prevalence of hereditary spastic paraplegia in Sardinia, insular Italy

Mapping the differences in care for 5,000 Spinal Muscular Atrophy patients, a survey of 24 national registries in North America, Australasia and Europe

Pallidal stimulation for primary generalised dystonia: effect on cognition, mood and quality of life

“Sand-watch” spinal cord: a case of inferior cervical spinal cord atrophy

Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study